



NANOBIOTIX receives 1 million euro from OSEO

Paris, France - November 24th 2011 - NANOBIOTIX a company developing cancer novel nanotherapeutics, announced today to receive a 1 million euro in grant from OSEO - French state innovation agency - within the context of NanoXray development.

Philippe Dhamelinourt, President of Matignon Investissement & Gestion, says "*this grant shows interest and commitments of OSEO by the side of Nanobiotix. It highly contributes to support the ongoing research and development of local cancer treatments.*"

Kader Boussaha, Co-founder and General Manager of Nanobiotix, adds: "*OSEO confirms its support to Nanobiotix by granting this new funding of 1 million. This financial backing comes right on time at a key milestone for Nanobiotix : the company announced recently that its lead compound NBTXR3, the most advanced product of NanoXray pipeline, has received the formal authorization from the French Medicine Agency, AFSSAPS to start the first clinical trial.*"

This sign of confidence is the opportunity to remind the significant support of OSEO in favor of Nanobiotix. Since its creation, the company awarded numerous prizes, all related to innovations and dynamism shown in local cancer treatment.

NBTXR3 clinical Trial

27 patients diagnosed with soft tissue sarcoma will be enrolled in the Phase I study and will receive NBTXR3 as an intra-tumoral injection with radiotherapy prior to surgery (first-line treatment) (www.clinicaltrials.gov). The primary endpoints of the clinical trial are the feasibility of NBTXR3 administration and safety¹. Preliminary data are expected by the end of 2012.

ABOUT NANOXRAY

Radiotherapy is used to treat about 50 to 60% of all cancer patients. It is known to be an effective treatment, but its efficacy is counteracted by the side effects in healthy tissue as the radiotherapy beam always needs to cross healthy tissue to reach the tumor. Radiotherapy therefore has a relatively narrow therapeutic window with a considerable need for improvement. Nanobiotix has developed a new class of therapeutics based on nanoparticles called [NanoXray](#) therapeutics. They consist of inert nanoparticles designed to enter tumor cells. Upon activation by a standard dose of radiation, NanoXray therapeutics release a tremendous amount of electrons, leading to the formation of radicals that destroy the cancer cells. As shown in preclinical experiments, this release should be restricted to the tumor as the particles are delivered selectively to the tumor site. The surrounding healthy

¹ Clinical trial, registration number RCB 2011-A00342-39

tissue is not affected and receives the normal radiation dose as in standard radiotherapy. Nanobiotix' goal is to significantly enhance the efficacy of radiotherapy within the tumor and to improve the clinical outcome of local treatment.

ABOUT NANBIOTIX – www.nanobiotix.com

Nanobiotix is a Paris, France, based nanomedicine company dedicated to the development of new cancer treatments. The company combines the advantages of nanotechnology and biotechnology. Nanobiotix is a spin-off of the State University of New York at Buffalo and was incorporated in 2003. It is funded by leading European venture capital firms (Maignon Technologies, OTC Asset Management, Cap Decisif, Amorcage Rhone-Alpes, CIC Vizille; Masseran Gestion-CGE). With the development of several new compounds, Nanobiotix's objective is to increase its leading position in the nanomedicine field.

www.oseo.fr

Contacts :

Agence Yucatan

Annie-florence Loyer

afloyer@yucatan.fr

+33 1 53 63 27 29/ +33 6 88 20 35 59

Nadège Le Lezec

nlelezec@yucatan.fr

+ 33 1 53 63 27 27